Ceftraixone induced anaphylaxis and death: a case report

A. Puranik
{"title":"Ceftraixone induced anaphylaxis and death: a case report","authors":"A. Puranik","doi":"10.18203/2319-2003.IJBCP20211030","DOIUrl":null,"url":null,"abstract":"Ceftriaxone, a broad spectrum third generation cephalosporin antibiotic and sulbactam is a beta-lactamase inhibitor. The combination is used for pre-operative surgical prophylaxis for prevention is secondary bacterial infection. We describe a patient who developed anaphylaxis and death soon after intravenous administration of ceftriaxone and sulbactam combination and review similar cases of adverse effects to these class of drugs. The patient was a 68 year old male admitted to surgery ward for obstructed inguinal hernia. He was prescribed injection ceftriaxone and sulbactam combination along with concomitant medication injection pantoprazole and injection metronidazole. The patient was injected injection ceftriaxone and sulbactam, within 15 minutes he suddenly developed anaphylactic shock and died for fluid aspiration in lungs during resuscitation. PubMed was searched for the following terms: anaphylaxis, ceftriaxone, sulbactam. The papers containing these terms and their references were reviewed. Anaphylactic shock caused by ceftriaxone is an uncommon adverse event in patients receiving the drug. However, similar reactions have been observed in some cases in India and world-wide. Clinicians should be aware that anaphylaxis secondary to ceftriaxone and sulbactam combination is a serious death threatening side-effect.","PeriodicalId":13898,"journal":{"name":"International journal of basic and clinical pharmacology","volume":"43 1","pages":"442"},"PeriodicalIF":0.0000,"publicationDate":"2021-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of basic and clinical pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18203/2319-2003.IJBCP20211030","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Ceftriaxone, a broad spectrum third generation cephalosporin antibiotic and sulbactam is a beta-lactamase inhibitor. The combination is used for pre-operative surgical prophylaxis for prevention is secondary bacterial infection. We describe a patient who developed anaphylaxis and death soon after intravenous administration of ceftriaxone and sulbactam combination and review similar cases of adverse effects to these class of drugs. The patient was a 68 year old male admitted to surgery ward for obstructed inguinal hernia. He was prescribed injection ceftriaxone and sulbactam combination along with concomitant medication injection pantoprazole and injection metronidazole. The patient was injected injection ceftriaxone and sulbactam, within 15 minutes he suddenly developed anaphylactic shock and died for fluid aspiration in lungs during resuscitation. PubMed was searched for the following terms: anaphylaxis, ceftriaxone, sulbactam. The papers containing these terms and their references were reviewed. Anaphylactic shock caused by ceftriaxone is an uncommon adverse event in patients receiving the drug. However, similar reactions have been observed in some cases in India and world-wide. Clinicians should be aware that anaphylaxis secondary to ceftriaxone and sulbactam combination is a serious death threatening side-effect.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
头孢曲松致过敏反应及死亡1例
头孢曲松是广谱第三代头孢菌素类抗生素,舒巴坦是β -内酰胺酶抑制剂。联合用药用于术前手术预防继发性细菌感染。我们描述了一位患者在静脉注射头孢曲松舒巴坦联合用药后不久发生过敏反应并死亡,并回顾了这类药物的类似不良反应病例。患者为男性,68岁,因梗阻性腹股沟疝住院。处方:头孢曲松舒巴坦联合注射,泮托拉唑注射,甲硝唑注射。患者经静脉注射头孢曲松舒巴坦,15分钟内突然发生过敏性休克,复苏过程中因肺部积液死亡。PubMed检索了以下术语:过敏反应,头孢曲松,舒巴坦。对包含这些术语及其参考文献的论文进行了审查。头孢曲松引起的过敏性休克在服用该药的患者中是一种罕见的不良事件。然而,在印度和世界各地的一些案例中也观察到类似的反应。临床医生应该意识到,头孢曲松和舒巴坦联合继发的过敏反应是一种严重的威胁死亡的副作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Assessment of KaraShieldTM properties in supporting the immune health of healthy subjects: a randomized, parallel, double-blind, placebo-controlled clinical study Knowledge attitude and practices of drug promotional literature: a clinician’s perspective Evaluation of β-blockers dosage regimen rationality in heart failure patients Perceptions of undergraduate medical students of old traditional and new CBME curriculum about pharmacovigilance and adverse drug reactions reporting at a tertiary care teaching hospital: a comparative study Comparison of efficacy of azilsartan with olmesartan in patients of hypertension: randomized controlled trial
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1